在ATR抑制剂Tuvusertib的临床开发中进行综合人群药理学,药动力学和安全性分析,以确定剂量选择.
在PubMed上查看摘要
概括
此摘要是机器生成的。基于模型的选择确定了180毫克QD2周/ 1周休息为推的tuvusertib扩张剂量. 这一剂量与每日100毫克一起,支持ATR抑制剂治疗的进一步临床评估.
科学领域
- 药理学和毒理学
- 癌症药物开发
- 定量系统药理学
背景情况
- 实验中的口服ATR抑制剂tuvusertib需要优化剂量以获得有效性和安全性.
- 之前的临床试验提供了药理动力学 (PK),药理动力学 (PD) 和剂量选择的安全数据.
- 了解药物暴露,目标参与和临床结果之间的关系至关重要.
研究的目的
- 通过综合定量药理学来确定tuvusertib的推扩张剂量 (RDE).
- 评估不同剂量方案对PK,PD和安全性的影响,包括血红蛋白降低和贫血.
- 评估服用假期对瘤生长抑制 (TGI) 的影响.
主要方法
- 开发了一个人群PK (POPPK) 模型来描述tuvusertib暴露和血红蛋白 (HGB) 减少.
- 使用半机械的POPPK/PD模型来模拟网状细胞 (RET),红细胞 (RBC) 和HGB动态.
- 在异种移植模型中使用PK-有效性模型评估度依赖的TGI和使用γH2AX生物标志物的临床暴露-PD关系.
主要成果
- 在POPPK模拟中,预测pCHK1 IC50的稳定状态度在100-180mgQD和180mgQD2w开/关.
- 预测目标参与率 (≥80%) 为≥130mgQD,其中180mgQD2w开启/ 1w关闭显示部分HGB恢复和较低的≥3级贫血率.
- 翻译模型表明,一周的休息时间对180mg的TGI没有影响.
结论
- 综合分析支持180mgQD2w开启/1w关闭为tuvusertib的RDE.
- 100毫克QD被确定为持续临床评估的"无后悔"剂量.
- 这项研究强调了定量药理学在通过综合证据方法来决定剂量选择中的价值.
相关概念视频
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

